Atai Life Sciences Future Growth
Future criteria checks 2/6
Atai Life Sciences is forecast to grow earnings and revenue by 47.5% and 65.7% per annum respectively. EPS is expected to grow by 52.7% per annum. Return on equity is forecast to be -129.6% in 3 years.
Key information
47.5%
Earnings growth rate
52.7%
EPS growth rate
| Pharmaceuticals earnings growth | 19.7% |
| Revenue growth rate | 65.7% |
| Future return on equity | -129.6% |
| Analyst coverage | Good |
| Last updated | 18 Nov 2024 |
Recent future growth updates
Recent updates
Psychedelic Stock Deep Dive: Atai Life Sciences
Sep 03Is Atai Life Sciences (NASDAQ:ATAI) Using Debt In A Risky Way?
Jul 15
ATAI: Enormous Potential Upside But No Clarity Yet
May 27Is Atai Life Sciences (NASDAQ:ATAI) Using Debt Sensibly?
Mar 02atai Life Sciences achieves positive results in phase 1 trial of kratom-derived drug
Oct 12Atai Life Sciences: Decentralized Drug Discovery Platform
Oct 06ATAI Life Sciences GAAP EPS of -$0.24 misses by $0.01
Aug 15We're Hopeful That Atai Life Sciences (NASDAQ:ATAI) Will Use Its Cash Wisely
Aug 07Atai Life Sciences: Leading But Early Stage Psychedelic Therapeutics Developer
Jul 07atai Life Sciences company Kures Therapeutics appoints Dr. Chad Beyer as CEO
Jun 30Atai Life Sciences N.V.: A First Take
Jun 02Atai Life Sciences And The Future Of Psychedelics For Mental Health
May 27We're Hopeful That Atai Life Sciences (NASDAQ:ATAI) Will Use Its Cash Wisely
Apr 22Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | 77 | -89 | -170 | -163 | 5 |
| 12/31/2026 | 0 | -138 | -148 | -143 | 6 |
| 12/31/2025 | 0 | -119 | -121 | -116 | 6 |
| 12/31/2024 | 1 | -129 | -85 | -84 | 6 |
| 9/30/2024 | 0 | -129 | -80 | -80 | N/A |
| 6/30/2024 | 0 | -58 | -79 | -79 | N/A |
| 3/31/2024 | 0 | -34 | -86 | -86 | N/A |
| 12/31/2023 | 0 | -40 | -85 | -84 | N/A |
| 9/30/2023 | 0 | -67 | -93 | -93 | N/A |
| 6/30/2023 | 0 | -145 | -104 | -102 | N/A |
| 3/31/2023 | 0 | -149 | -103 | -102 | N/A |
| 12/31/2022 | 0 | -152 | -105 | -104 | N/A |
| 9/30/2022 | 0 | -196 | -97 | -94 | N/A |
| 6/30/2022 | 1 | -194 | -96 | -95 | N/A |
| 3/31/2022 | 0 | -205 | -73 | -71 | N/A |
| 12/31/2021 | 20 | -168 | -65 | -63 | N/A |
| 9/30/2021 | 20 | -166 | -50 | -49 | N/A |
| 6/30/2021 | 20 | -218 | -27 | -26 | N/A |
| 3/31/2021 | 20 | -185 | -34 | -33 | N/A |
| 12/31/2020 | N/A | -170 | -21 | -21 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ATAI is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ATAI is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ATAI is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ATAI's revenue (65.7% per year) is forecast to grow faster than the US market (9% per year).
High Growth Revenue: ATAI's revenue (65.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ATAI is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/22 23:51 |
| End of Day Share Price | 2025/01/22 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Atai Life Sciences N.V. is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Leonildo Delgado | Baader Helvea Equity Research |
| Sumant Satchidanand Kulkarni | Canaccord Genuity |
| Charles Duncan | Cantor Fitzgerald & Co. |